AstraZeneca's Evinova partners with Astellas and BMS to speed up clinical trials using its AI platform.
This collaboration signals a major industry shift towards AI-driven clinical development.
阿斯利康旗下的Evinova公司与安斯泰来和百时美施贵宝合作，利用其人工智能平台加速临床试验，并通过共享数据提供人工智能驱动的见解。
Evinova, AstraZeneca's health-tech business, announced strategic collaborations with Astellas and Bristol Myers Squibb to accelerate global clinical development using its AI-native platform. By sharing operational data, the partners will enable the platform to provide benchmarks and smarter recommendations. This aims to speed up clinical trials, reduce costs, and improve patient outcomes by moving from manual, fragmented processes to intelligent, AI-first workflows.
This collaboration signals a major industry shift towards AI-driven clinical development. By pooling data and leveraging AI, AstraZeneca and its partners can significantly shorten drug development timelines, reduce failure rates, and gain a competitive edge in bringing new therapies to market faster.
此信号在行业全局中的位置。
AstraZeneca's Datopotamab Deruxtecan Granted Fast Track Designation in US for Metastatic Lung Cancer
AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment
AstraZeneca's Enhertu Granted US Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
Health Canada approves Koselugo for adults with neurofibromatosis type 1
https://www.astrazeneca.com/media-centre/press-releases/2026/evinova-announces-strategic-collaborations-with-astellas-and-astrazeneca-to-scale-digital-health-solutions.html
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录